- Home
- QMCO vs GLSI Comparison
QMCO vs GLSI Comparison
Compare QMCO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QMCO
- GLSI
- Stock Information
- Founded
- QMCO 1980
- GLSI 2006
- Country
- QMCO United States
- GLSI United States
- Employees
- QMCO N/A
- GLSI N/A
- Industry
- QMCO Electronic Components
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- QMCO Technology
- GLSI Health Care
- Exchange
- QMCO Nasdaq
- GLSI Nasdaq
- Market Cap
- QMCO 157.2M
- GLSI 145.2M
- IPO Year
- QMCO N/A
- GLSI 2020
- Fundamental
- Price
- QMCO $8.17
- GLSI $8.70
- Analyst Decision
- QMCO Hold
- GLSI Strong Buy
- Analyst Count
- QMCO 2
- GLSI 1
- Target Price
- QMCO $19.00
- GLSI $39.00
- AVG Volume (30 Days)
- QMCO 1.2M
- GLSI 79.8K
- Earning Date
- QMCO 11-13-2025
- GLSI 11-14-2025
- Dividend Yield
- QMCO N/A
- GLSI N/A
- EPS Growth
- QMCO N/A
- GLSI N/A
- EPS
- QMCO N/A
- GLSI N/A
- Revenue
- QMCO $266,079,000.00
- GLSI N/A
- Revenue This Year
- QMCO N/A
- GLSI N/A
- Revenue Next Year
- QMCO $5.30
- GLSI N/A
- P/E Ratio
- QMCO N/A
- GLSI N/A
- Revenue Growth
- QMCO N/A
- GLSI N/A
- 52 Week Low
- QMCO $2.88
- GLSI $7.88
- 52 Week High
- QMCO $90.64
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- QMCO 36.74
- GLSI 38.48
- Support Level
- QMCO $8.90
- GLSI $8.02
- Resistance Level
- QMCO $11.28
- GLSI $9.51
- Average True Range (ATR)
- QMCO 0.63
- GLSI 0.57
- MACD
- QMCO -0.32
- GLSI -0.06
- Stochastic Oscillator
- QMCO 19.13
- GLSI 31.88
About QMCO Quantum Corporation
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.